the stent is less than 0.5 % and the stent strut/vessel area ratio varies between 15-18 %. 4 The stent is crimped on a bottle-shaped balloon (Bottle ® , Balton, Warsaw, PL) (see Figure 1 ). Bottle ® balloons are available in a wide range of sizes and lengths allowing the left main (LM) treatment as well. The balloon nominal pressure is 10 atm, whereas the rated burst pressure is 18 atm. The balloon is semi-complaint with an increase in a diameter size of 0.25 mm at 12 atm, both proximally and distally.
The rapid exchange delivery system for the BiOSS LIM ® stent is compatible with 0.014" guide wires and with 5 Fr (1.63 mm internal diameter) guiding catheters. The BiOSS LIM ® stent is introduced over a single guide wire, which (contrary to other dedicated systems guided on two guide wires) eliminates the risk of wire wrap (twisting) or other complications with double guide wire-driven systems. Worth mentioning is the fact that the BiOSS LIM ® stent was also implanted in bifurcations located in peripheral arteries, i.e. below the knee. 5 
BiOSS LIM ® -The Mechanism of Action
After wiring the MB and the SB, predilations can be performed according to the operator's preferences. The BiOSS LIM ® stent's delivery balloon has three markers: distal and proximal indicating stent edges and one mid-marker showing the mid-zone. The midmarker should be placed exactly at the tip of the carina. This ensures that after deployment the contralateral to SB wall is covered with struts to the same extent as the proximal MV part of the bifurcation (see Figure 2 ). This is achieved by the self-centring properties of the device (due to special shape of connecting struts) and the 'closure' configuration between the proximal and distal parts of the stent. The BiOSS LIM ® design reduces the risk of carina shift as well as the SB ostium compromise. 6 Additionally, the Bottle ® balloon shape ensures the proximal optimisation technique (POT)-like effect immediately after BiOSS ® implantation; however, post-dilation of its proximal part (real POT) seems to improve clinical results. 7 Also, its ease-of-use allows the implantation of two BiOSS LIM ® stents in a culottes fashion in distal LM stenosis. 8 Since the beginning, the BiOSS LIM ® stent construction provoked the question whether a 2.0-2.4 mm long middle zone of that stent was the weakest part predisposing to restenosis and intrastent thrombosis.
An intravascular ultrasound (IVUS) study on the device in non-LM bifurcations disclosed a different mechanism of lumen enlargement in coronary bifurcation lesions treated with a provisional approach between classic DES and the BiOSS ® stents. Although, the comparable luminal gain was observed, the BiOSS ® stent was associated with less luminal compromise and plaque redistribution at the level of the SB in-flow in the bifurcation segment. 6 Moreover, the analysis of restenosis patterns in POLBOS I, in the FIM BiOSS LIM ® Registry, as well as in the BiOSS LIM ® in LM registry denies those assumptions. Table 1 . After acceptable results of the BiOSS Expert ® stent in the all-comer population, 11 as well as in distal LM stenosis, 10 a way for improvement was to change the paclitaxel into the -olimus drug. The sirolimus was chosen and the BiOSS LIM ® stent was developed. 
BIOSS LIM ® Registries
In the First-in-Man trial, 60 patients from three countries were enrolled angiographically driven 6.6 %). The SB was treated with an additional classic DES implantation in 23.3 % of cases. 12 The comparison of BiOSS Expert ® FIM and BiOSS LIM ® FIM results are presented in Table 2 .
In the second registry, 74 cases with distal LM were analysed. In both cases our experience showed that this device is extremely user-friendly. The vast majority of implantations were possible using radial access (more than 90 %) and 6 F compatible equipment (including also LM cases). Moreover, such a stent ensured ideal immediate efficacy (100 % device success rate!) It is worth stressing the fact of easy rewiring of SB after BiOSS ® Expert stent implantation. This device success rate is clearly superior to all reported in the literature data about procedural success rate of other dedicated coronary bifurcation stents (70-98 % for other types of devices). This high success rate is a result of the obvious lack of problems frequently occurring with other dedicated devices, like guide wires criss-crossing, improper device orientation and a rather big profile of the device.
What must also be stressed during the BiOSS LIM ® development different drug concentrations were used. As presented in Table 3 the use of higher concentration of sirolimus was associated with lower late lumen loss.
Randomised Clinical Trials
The POLBOS I study was the first randomised clinical trial. 7 The aim of the POLBOS I trial was to compare bifurcation treatment with any classic DES to the dedicated bifurcation paclitaxel-eluting stent were paclitaxel-eluting stents. There were three stent implantation failures (two in DES; one in the BiOSS group). Side-branch treatment with DES was required in 10 % of cases in both groups. At 12 months, cumulative MACE incidence was similar in both groups:
BiOSS Expert
13.3 % versus 12.2 % (p=0.7). The TLR rate was significantly higher in the BiOSS Group compared with DES: 11.5 % versus 7.3 % (p=0.02).
In further analysis, when comparing the BiOSS Group to only the PES subgroup from DES, the rate of TLR in both groups was similar (11.5 % versus 10.6 %). Moreover, when comparing LM bifurcation versus non-LM bifurcation lesions BiOSS Expert ® was significantly superior to DES in treatment of distal LM stenosis (TLR: 7.4 % versus 11.1 %, p=0.04). The rates of clinically driven TLR in our study were markedly lower in BiOSS as well as in DES Groups, 5.8 % and 3.2 % (NS), respectively. This is similar to the best results of DES in coronary bifurcation treatment (see Table 4 ). 
The Future of BiOSS ® Programme
Results of stainless steel thick-strut stent BiOSS ® LIM look interesting. CrCo is being prepared, where it will be compared with the Xience ® and Resolute ® stents.
Conclusions
Our experience with BiOSS ® stent let us conclude that this device is easy to use and compatible with modern low-profile stents. The elimination of carina displacement (as a main mechanism of SB compromise) by BiOSS ® stent keeps the SB patent and do not require further treatment. The wide range of available sizes allows the majority of bifurcation patterns to be successfully treated. n 
